327 related articles for article (PubMed ID: 16981664)
1. New therapeutic options for renal cell carcinoma.
Stadler W
Clin Adv Hematol Oncol; 2006 Jun; 4(6):429-30. PubMed ID: 16981664
[No Abstract] [Full Text] [Related]
2. Two new drugs for renal cell carcinoma.
Med Lett Drugs Ther; 2007 Feb; 49(1255):18-20. PubMed ID: 17325624
[No Abstract] [Full Text] [Related]
3. Kidney cancer: Does hypothyroidism predict clinical outcome?
Rini B
Nat Rev Urol; 2011 Jan; 8(1):10-1. PubMed ID: 21116300
[No Abstract] [Full Text] [Related]
4. [Role of VEGFR-TKIs in the treatment of renal cell carcinoma].
Kondo T
Nihon Jinzo Gakkai Shi; 2012; 54(5):574-80. PubMed ID: 22991835
[No Abstract] [Full Text] [Related]
5. Newly approved therapies for RCC and their effect on the standard of care.
Figlin RA
Clin Adv Hematol Oncol; 2007 Jan; 5(1):35-6, 66. PubMed ID: 17339824
[No Abstract] [Full Text] [Related]
6. [New drugs; sunitinib and sorafenib].
van Bronswijk H; Dubois EA; Osanto S; Cohen AF
Ned Tijdschr Geneeskd; 2007 Dec; 151(52):2888-90. PubMed ID: 18257434
[TBL] [Abstract][Full Text] [Related]
7. Editorial comment.
Rini BI; Shah SN
Urology; 2010 May; 75(5):1114-5; author reply 1115. PubMed ID: 20451727
[No Abstract] [Full Text] [Related]
8. Editorial comment.
Vaishampayan U
Urology; 2010 May; 75(5):1114; author reply 1115. PubMed ID: 20451726
[No Abstract] [Full Text] [Related]
9. CCR drug updates: sorafenib and sunitinib in renal cell carcinoma.
Stein MN; Flaherty KT
Clin Cancer Res; 2007 Jul; 13(13):3765-70. PubMed ID: 17606705
[No Abstract] [Full Text] [Related]
10. [Renal cell carcinoma].
Oya M
Gan To Kagaku Ryoho; 2010 Jan; 37(1):29-31. PubMed ID: 20140991
[No Abstract] [Full Text] [Related]
11. Tyrosine kinase inhibitors in advanced renal cell carcinoma: the evolving treatment paradigm.
Bukowski RM
Clin Genitourin Cancer; 2009 Jan; 7(1):9-10. PubMed ID: 19213661
[No Abstract] [Full Text] [Related]
12. [Efficacy of multikinase inhibitors in the treatment of advanced renal cell cancer. A snapshot].
Kuczyk M; Kruck S; Merseburger AS
Urologe A; 2007 May; 46(5):504-8, 510. PubMed ID: 17437075
[TBL] [Abstract][Full Text] [Related]
13. Acute exacerbation of hemorrhagic rectocolitis during antiangiogenic therapy with sunitinib and sorafenib.
Loriot Y; Boudou-Rouquette P; Billemont B; Ropert S; Goldwasser F
Ann Oncol; 2008 Nov; 19(11):1975. PubMed ID: 18723549
[No Abstract] [Full Text] [Related]
14. Efficacy of sunitinib and sorafenib in non-clear cell renal cell carcinoma: results from expanded access studies.
Strumberg D
J Clin Oncol; 2008 Jul; 26(20):3469-71; author reply 2471. PubMed ID: 18612169
[No Abstract] [Full Text] [Related]
15. Genetic basis of kidney cancer: a model for developing molecular-targeted therapies.
Vira MA; Novakovic KR; Pinto PA; Linehan WM
BJU Int; 2007 May; 99(5 Pt B):1223-9. PubMed ID: 17441915
[No Abstract] [Full Text] [Related]
16. [Renal cell carcinoma].
Obara W; Fujioka T
Gan To Kagaku Ryoho; 2008 Sep; 35(9):1482-7. PubMed ID: 18799901
[TBL] [Abstract][Full Text] [Related]
17. Multitargeted agents for therapeutically challenging tumor: an introduction for oncology nurses.
King CR
ONS News; 2006; 21(8 Suppl):57-8. PubMed ID: 16925154
[No Abstract] [Full Text] [Related]
18. Managing side effects of angiogenesis inhibitors in renal cell carcinoma.
Grünwald V; Heinzer H; Fiedler W
Onkologie; 2007 Oct; 30(10):519-24. PubMed ID: 17890892
[TBL] [Abstract][Full Text] [Related]
19. Secondary erythrocytosis produced by the tyrosine kinase inhibitors sunitinib and sorafenib.
Alexandrescu DT; McClure R; Farzanmehr H; Dasanu CA
J Clin Oncol; 2008 Aug; 26(24):4047-8. PubMed ID: 18711201
[No Abstract] [Full Text] [Related]
20. [New therapeutic regimes in metastasic renal-cell carcinoma].
Bierer S; Hertle L; Nitschmann S
Internist (Berl); 2008 Jan; 49(1):114-7. PubMed ID: 18704353
[No Abstract] [Full Text] [Related]
[Next] [New Search]
